Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases

Joanna M. Kułdo, Ken Ichi Ogawara, Naomi Werner, Sigridur A. Ásgeirsdóttir, Jan A A M Kamps, Robbert J. Kok, Grietje Molema

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.

Original languageEnglish
Pages (from-to)11-39
Number of pages29
JournalCurrent Vascular Pharmacology
Volume3
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Chronic Disease
Endothelial Cells
Pharmacology
Cytokines
Drug Carriers
Fibroblast Growth Factors
Mitogen-Activated Protein Kinases
Interleukin-1
Chemokines
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Reactive Oxygen Species
Signal Transduction
Intercellular Signaling Peptides and Proteins
Nitric Oxide
Cell Culture Techniques
Tumor Necrosis Factor-alpha
Oxygen
Gene Expression
Food

Keywords

  • Angiogenesis
  • Chronic inflammation
  • Drugs
  • Endothelial cells
  • Pharmacology
  • Signal transduction
  • Vascular drug targeting

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Kułdo, J. M., Ogawara, K. I., Werner, N., Ásgeirsdóttir, S. A., Kamps, J. A. A. M., Kok, R. J., & Molema, G. (2005). Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Current Vascular Pharmacology, 3(1), 11-39. https://doi.org/10.2174/1570161052773898

Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. / Kułdo, Joanna M.; Ogawara, Ken Ichi; Werner, Naomi; Ásgeirsdóttir, Sigridur A.; Kamps, Jan A A M; Kok, Robbert J.; Molema, Grietje.

In: Current Vascular Pharmacology, Vol. 3, No. 1, 01.2005, p. 11-39.

Research output: Contribution to journalArticle

Kułdo, Joanna M. ; Ogawara, Ken Ichi ; Werner, Naomi ; Ásgeirsdóttir, Sigridur A. ; Kamps, Jan A A M ; Kok, Robbert J. ; Molema, Grietje. / Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. In: Current Vascular Pharmacology. 2005 ; Vol. 3, No. 1. pp. 11-39.
@article{a8b86d9523324a7baffe130d5e8353a2,
title = "Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases",
abstract = "In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.",
keywords = "Angiogenesis, Chronic inflammation, Drugs, Endothelial cells, Pharmacology, Signal transduction, Vascular drug targeting",
author = "Kułdo, {Joanna M.} and Ogawara, {Ken Ichi} and Naomi Werner and {\'A}sgeirsd{\'o}ttir, {Sigridur A.} and Kamps, {Jan A A M} and Kok, {Robbert J.} and Grietje Molema",
year = "2005",
month = "1",
doi = "10.2174/1570161052773898",
language = "English",
volume = "3",
pages = "11--39",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases

AU - Kułdo, Joanna M.

AU - Ogawara, Ken Ichi

AU - Werner, Naomi

AU - Ásgeirsdóttir, Sigridur A.

AU - Kamps, Jan A A M

AU - Kok, Robbert J.

AU - Molema, Grietje

PY - 2005/1

Y1 - 2005/1

N2 - In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.

AB - In chronic inflammatory conditions, endothelial cells actively recruit immune cells from the circulation into the underlying tissue and participate in angiogenesis to support the continuous demand for oxygen and nutrients. They do so in response to activation by cytokines and growth factors such as tumour necrosis factor α (TNFα), interleukin-1 (IL-1), vascular endothelial growth factor (VEGF), and fibroblast growth factors (FGFs). Receptor triggering initiates intracellular signal transduction leading to activation of nuclear factor κB (NFκB), mitogen activated protein kinase (MAPK) activity, and nitric oxide and reactive oxygen species production, among others. As a result, adhesion molecules, cytokines and chemokines, and a variety of other genes are being expressed that mediate and control the inflammatory process. In recent years, different classes of drugs have been developed that interfere with selected enzymes involved in the intracellular signalling cascades. In endothelial cell cultures, they exert potent inhibitory effects on the expression of genes, while several studies also report on in vivo effectiveness to confine the inflammatory responses. To prevent undesired toxicity and to improve drug behaviour and efficacy, drug carrier systems have been developed that selectively deliver the therapeutics into the activated endothelial cells. The above subjects are recapitulated to give an overview on the status of development of endothelial cell directed therapeutic strategies to pharmacologically interfere with chronic inflammatory diseases.

KW - Angiogenesis

KW - Chronic inflammation

KW - Drugs

KW - Endothelial cells

KW - Pharmacology

KW - Signal transduction

KW - Vascular drug targeting

UR - http://www.scopus.com/inward/record.url?scp=11844270511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844270511&partnerID=8YFLogxK

U2 - 10.2174/1570161052773898

DO - 10.2174/1570161052773898

M3 - Article

C2 - 15638780

AN - SCOPUS:11844270511

VL - 3

SP - 11

EP - 39

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 1

ER -